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Abstract 
The present article is aimed to outline the current state of knowledge regarding the effects of 
lipoprotein(a) (Lp(a)) on cardiovascular disease (CVD) risk by summarizing the recent results of 
studies, meta-analyses and systematic reviews. The literature supports the predictive value of 
Lp(a) on CVD outcomes, although the effect size is modest. Lp(a) would also appear to have an 
effect on cerebrovascular outcomes, with the effect appearing even smaller than that for CVD 
outcomes. Consideration of apolipoprotein apolipoprotein(a) (apo (a)) isoforms and LPA 
genetics in relation to the simple assessment of Lp(a) concentration may enhance improving 
clinical practice in vascular medicine. We also describe recent advances in Lp(a) research 
(including therapies) and highlight areas where further research is needed such as the 
measurement of Lp(a) and its involvement in additional pathophysiological processes. 
 
Keywords: apo(a), cardiovascular disease, cerebrovascular disease, coronary heart disease, Lp(a), 
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Introduction 
A variety of lipids and lipoproteins are involved in the development of vascular pathologies 
1-8. The role of lipoprotein(a) (Lp(a)) on health and disease has long been of interest 9. Lp(a) is a 
unique and still enigmatic lipoprotein particle, composed by a covalent association mediated by a 
single disulphide bridge between apolipoprotein B100 (ApoB100; the main protein moiety of low-
density lipoprotein (LDL)) and apolipoprotein(a) (apo(a), a hydrophilic glycoprotein) 10-14 
(Figure 1). Apo(a) has a high degree of structural homology with plasminogen and can hence 
antagonize both in vivo and in vitro activity of the patter enzyme 15. Due to its similarity with 
LDL and the structural homology with plasminogen, Lp(a) plays an atherothrombotic action 13.  
Although the definitive metabolism of Lp(a) remains to be completely defined, biological 
evidence seemingly attests that apo(a) is secreted by the liver, rapidly associated with apoB100 in 
the circulation, whereas its catabolism pathway is then mainly sustained by the liver (via the 
hepatic scavenger receptor class B type I and LDL receptor), spleen and kidney 13, 16. 
Intriguingly, a large part of the circulating Lp(a) level is heritable, with its genetic components 
located in the LPA gene responsible for the encoding of apo(a) 17-22. However, Lp(a) 
concentrations are also dependent on the rate of hepatic apo(a) and apoB100 secretion 23. A recent 
study showed that free apo(a) has a plasma residence time of approximately 11 days compared to 
only 4 days when the protein is bound to apoB100 within the Lp(a) particle, thus supporting the 
concept of an individual metabolism for these components 24. 
 Studies of Lp(a) have led to the increasing recognition of its role as a risk biomarker 
causally associated with vascular pathologies 10, 25. However, circulating Lp(a) concentrations 
above 50 mg/dL but less than 200 mg/dL are found in <1% of the general population 11. A 
greater understanding of the pathophysiological roles of Lp(a) may lead to clinical measurements 
of Lp(a) as part of risk prediction and management of cardiovascular disease (CVD). However, 
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the heritable nature of Lp(a) concentrations would raise questions about who should be screened 
for and at what age. Lp(a) is modulated by several drugs and presents an interesting therapeutic 
target 26. In this review, we aim to summarize and share current knowledge regarding the 
relationship between Lp(a) and vascular diseases, and to describe other interesting features of 
this intriguing lipoprotein particle. To date, there have been numerous review papers on the 
implications of Lp(a) for vascular medicine. We based the present paper on the meta-analyses, 
which were conducted on this topic, thus ensuring that our discussion reflects the highest quality 
available evidence. 
 
Lp(a) and cardio- and cerebrovascular disease: an updated summary of evidence 
 A search of PubMed/Medline was performed to discover all the papers written in an 
English-language and published before January 15, 2016. The title terms ‘lipoprotein (a)’ or ‘Lp 
(a)’ and ‘meta-analysis’ or ‘meta analysis’ or ‘metaanalysis’ or ‘systematic review’ or ‘study’ or 
‘trial’ were used. From the results, we selected high-quality and relevant meta-analyses for 
inclusion and discussion in this review. We supplemented these with other high-quality papers to 
expand the scope our work to other aspects of Lp(a) in health and disease. 
 The relationship between Lp(a) and CVD outcomes has been confirmed by at least three 
meta-analyses 27-29 (Table 1). An earlier meta-analysis (published in 1998) also suggested that 
Lp(a) is  a risk marker for CVD 30. The statistical methods of the meta-analysis were identical 
with those used in more recent studies; accordingly, this paper was not included here. Although 
all the three papers used prospective studies in the meta-analysis 27-29, this presented some 
difficulties as the outcomes of trials could not be divided into fatal and nonfatal events, or the 
study populations could not be divided into primary and secondary prevention groups. One meta-
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analysis reported a significant prognostic value of Lp(a) on coronary heart disease (CHD) events 
by comparing the frequency of CHD deaths or myocardial infarction (MI) in patients with high 
and low baseline levels of Lp(a) 27. The relative risk (RR) associated with high Lp(a) in the entire 
population was 1.6 (95% CI, 1.4 to 1.8; p<0.00001). In a subpopulation of patients with previous 
coronary disease the relative risk was 1.3 (95% CI, 1.1 to 1.6; p<0.001) 27. A subsequent study 
reported a significant prognostic value of Lp(a) on CHD events (RR, 1.13 and 95% CI, 1.09 to 
1.18 per 3.5-fold higher usual Lp(a) concentration, i.e., per 1 standard deviation) 28. A more 
recent study has reported a significant prognostic value of Lp(a) on CHD events (RR of the 
entire population, 1.57 and 95% CI, 1.41 to 1.75, p < 0.001; RR of a subpopulation with previous 
coronary disease, 2.37 and 95% CI, 1.41 to 3.97, p=0.001) 29. More recently, a review paper 
summarizing population-based studies has also described a continuous positive association 
between Lp(a) and the risk of CVD events 31. Thus, a prognostic value of elevated Lp(a) on CHD 
events has been repeatedly confirmed, although the magnitude of the effect appears to be 
globally modest.  
 The predictive value of Lp(a) on CHD events in a population with a previous history of 
coronary disease shows great variability between the first study (RR of a population with 
previous coronary disease, 1.30, that is lower compared to that of an entire population) 27 and the 
recent study (RR of a population with previous coronary disease, 2.37, which is higher compared 
to that of an entire population) 29. Further work is needed to resolve this discrepancy. 
Additionally, a review paper pointed out that in the presence of a high level of LDL, the 
association between Lp(a) and risk of CVD events was enhanced 31. This also warrants further 
investigation. 
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 The relationship between Lp(a) concentrations and cerebrovascular outcomes has been 
determined in at least three meta-analyses 28, 29, 32, with both fatal and nonfatal events as 
outcomes. The first paper reported a significantly high Lp(a) level and a more frequent existence 
of elevated Lp(a) concentrations ≥30 mg/dL (odds ratio [OR], 2.39; 95% CI, 1.57 to 3.63) in 
patients with stroke than in those without (this used case-control studies) 32. Including 
prospective studies, a significantly greater number of stroke events was observed in the highest 
tertile of Lp(a) distribution than in the lowest tertile (RR, 1.22; 95% CI, 1.04 to 1.43) 32. A 
subsequent article described a significant prognostic value of Lp(a) on ischemic stroke events 
(RR, 1.1 and 95% CI, 1.02 to 1.18 per 3.5-fold higher usual Lp(a) concentration (i.e., per 1 
standard deviation)) 28. On the other hand, another study reported no apparent prognostic value 
of Lp(a) on stroke (RR, 1.10 and 95% CI, 0.97 to 1.25; p=0.14) 29. Thus, a prognostic value of 
Lp(a) on cerebrovascular (stroke) events is suggestively confirmed, but still inconsistent (Table 
1). 
Importantly, the magnitude of the prognostic value of Lp(a) on stroke events appeared to be 
low compared to that of Lp(a) on CVD events. This might be at least in part attributable to the 
more complicated pathogenetic mechanisms related to the development of stroke compared to 
those involved in CHD. Similar differences have been also observed by comparing the effect of 
blood pressure lowering 33 as well as the effect of LDL-cholesterol reduction (especially in 
secondary prevention patients) 34 on stroke versus the other CVD outcomes. Therefore, the effect 
of Lp(a) on stroke events 35, 36 is still hard to establish. On the other hand, in a more recent meta-
analysis, including 20 trials and totaling 90,904 subjects and 5029 stroke events, an increased 
Lp(a) concentration has been reported to be an independent risk factor for ischemic stroke (OR, 
1.41 and 95% CI, 1.26 to 1.57 for case-control studies; RR, 1.29 and 95% CI, 1.06 to 1.58 for 
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prospective studies), mainly pertinent for young patients (≤55 years of age) who suffered from 
stroke 37.  
It was also hypothesized that the predictive role of Lp(a) on CVD and stroke events might be 
associated with inflammation. The role of inflammation or normal food intake in predicting CHD 
was assessed in 34,829 Danish participants included in the Copenhagen City Heart Study and the 
Copenhagen General Population Study 38. This study showed that increased levels of C-reactive 
protein (CRP) were minimally associated with increased Lp(a) concentrations, and the Lp(a) 
value was not significantly modified by normal food intake 38. A multidirectional Mendelian 
randomization approach including 100,578 Danish individuals then proved no association 
between plasma Lp(a) concentrations and low-grade inflammation, despite the causal association 
with increased risk of myocardial infarction and aortic valve stenosis 39. 
Evidence is being accumulated in terms of the role of Lp(a) on CVD risk. All above issues 
would deserve further investigation to finally establish the prognostic value of Lp(a) on cardio- 
and cerebro-vascular outcomes.  
 
Lp(a) and cardiometabolic and vascular disease: a unique insight 
 In recent years, additional meta-analyses and systematic reviews focused on the clinical 
significance of Lp(a) for vascular diseases have been published (Table 2). First, a meta-analysis 
which included population-based observational studies has examined the relationship between 
apo(a) and cardio- and cerebrovascular disease risk 40. Apo(a) is a heritable modulator of Lp(a) 
effects and smaller apo(a) isoforms have been convincingly shown to be associated with higher 
Lp(a) levels 15, 17-22. A significant association between smaller apo(a) isoforms and CHD events 
compared with larger apo(a) isoforms was described by Erqou et al (RR, 2.08; 95% CI, 1.67 to 
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2.58) 40. A significant association was also appreciated between smaller apo(a) isoforms and 
ischemic stroke events compared with larger apo(a) isoforms (RR, 2.14; 95% CI, 1.85 to 2.97) 40. 
The impact of apo(a) on CHD events might be related to Lp(a) concentrations. However, few 
studies included in this meta-analysis adjusted the data for Lp(a) values for exploring the 
relationship between apo(a) and outcomes 40.  
 Two different meta-analyses, involving case-control studies, investigated the role of Lp(a) in 
non-CVD pathologies 41, 42. One article explored the relationship between Lp(a) and venous 
thrombembolism (VTE). It has been reported that a significant association may exist between 
increased Lp(a) levels (i.e., >30 mg/dL) and VTE (OR, 1.87; 95% CI, 1.51 to 2.30) 41. The 
influence of Lp(a) on arterial pathologies is well-documented, but this article described new 
insights into the role of Lp(a) in venous pathologies. Another meta-analysis investigated the 
relationship between CVD risk based on Lp(a) levels and polycystic ovary syndrome (PCOS) 42. 
It was reported that women with PCOS had significantly higher Lp(a) levels than controls 
(standardized mean difference, 0.81; 95% CI, 0.58 to 1.04) 42. Notably, it is hence reasonable to 
put forward an hypothesis that the cardiometabolic propensity in PCOS may be partly caused by 
Lp(a). 
  Here, we would add the finding from a recent study (although it was not the meta-analysis 
and systematic review), the Copenhagen City Heart Study (CCHS) and the Copenhagen General 
Population Study (CGPS), has also shown that there is a causal association between increased 
Lp(a) concentrations, corresponding LPA risk genotypes, and increased risk of heart failure 43. 
The association was partially mediated by myocardial infarction and aortic valve stenosis 43. 
 Finally, a systematic review comprising 6 observational studies, described the relationship 
between Lp(a) and familiar hypercholesterolemia (FH) in children 44. No apparent relationship 
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between Lp(a) and FH in children was noticed 44. The levels of Lp(a) were found to be higher in 
FH children, but this association remains controversial 45, 46. The management of FH in 
childhood is commonplace to prevent adverse cardiovascular effects 47, 48. To date, the levels of 
Lp(a) have been poorly described in FH children, since only a few studies comprising a small 
number of patients have addressed this association. Therefore, the need of further studies has 
been proposed although the data were negative 47 (Table 2).  
 
Update on therapies for modulating Lp(a) 
 Apheresis is the most effective technique to reduce circulating Lp(a) concentrations up to 
75% from the baseline levels 49. Lp(a) is quite refractory to both drug intervention and lifestyle 
49, 50. Currently, therapeutic apheresis is recommended by most lipid and atherosclerosis societies 
only in cases of severe FH 51. The HEART-UK and the German Committee of Physicians and 
Health Insurance Funds also recommended apheresis for individuals with progressive CHD and 
plasma Lp(a) concentrations higher than 60 mg/dL 52, 53. However, plasma Lp(a) concentrations 
generally returned to baseline levels only two weeks after apheresis (which is compatible with 
the biological half-life of this enigmatic lipoprotein paticle), thus limiting the potential benefits 
of this technique, as well as reducing the quality of life of these patients 52, 54. 
 Various drugs and nutraceutical interventions have been investigated in experimental and 
clinical settings as modulators of plasma Lp(a) concentrations. Moreover, few societies have 
tried to identify the best therapeutic options to reduce Lp(a) concentrations. A target level of 
Lp(a) below 50 mg/dL, as a feature of global CVD risk, has been recommended by the European 
Atherosclerosis Society (EAS) Consensus Panel in 2010 11. Both the American Heart 
Association (AHA)/American Stroke Association (ASA) and the European Society of 
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Atherosclerosis (EAS) guidelines recommended 1-3 grams nicotinic acid (niacin, vitamin B3) 
daily for the treatment of increased Lp(a) concentrations 11, 55, 56. In a randomized, crossover trial 
of 12-weeks, it has also been reported that extended-release niacin (1-2 grams) daily may be 
effective to reduce Lp(a) concentrations via reducing apo(a) and apoB100 production in statin-
treated men with type 2 diabetes mellitus 57. A simvastatin-niacin combination was found to be 
effective to reduce Lp(a) concentrations up to 21%, but such a reduction was not associated with 
lower CVD events in the Atherothrombosis Intervention in Metabolic Syndrome with Low 
HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) study 58. Another 
recent 24-week, prospective, open-label clinical trial evaluated the impact of extended-release 
(ER) niacin on plasma Lp(a) concentrations in function of apo(a) phenotype 59. Indeed, high-
dose ER niacin decreased plasma Lp(a) concentrations only in male subjects with low-molecular 
weight apo(a) phenotype 59. However, different adverse effects have been noticed in clinical 
practice through increased production of prostaglandin D(2) and E(2) after niacin therapy that 
limits the widespread use of this drug 60. Favorable effects of statins on lipid metabolism are well 
known. Atorvastatin is reported to reduce Lp(a) 61, while in general, plasma Lp(a) concentrations 
remain unchanged after this therapy, which may help to explain residual CVD risk in general 
population and FH individuals treated with statins 62, 63. Fibrates, which are lipid-lowering drugs 
intracting with the Peroxisome Proliferator Activated Receptor alpha (PPARα), were also 
proposed as plasma Lp(a)-reducing drugs, but further studies remain warranted 64. Thyroid 
mimetics, despite favorable effects through increased expression of hepatic LDL receptor and 
increasing clearance of LDL in the circulation, were discontinued in 2012 after notable side-
effects 65. 
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 Recently, much attention has been paid to several new drugs for modulating lipoproteins. 
Lomitapide (Juxtapid, Aegerion, Cambridge, MA), an inhibitor of microsomal triglyceride 
transfer protein (MTP), was shown to reduce plasma Lp(a) concentrations by 17% in 
hypercholesterolemic patients 66. A study on individuals with homozygous FH showed a 
decrease by 15% of plasma Lp(a) concentrations after 26 weeks of lomitapide therapy 67.  
 There have been also data concerning the role of hormonal drugs on Lp(a) reduction. A 
recent meta-analysis of 12 RCTs with 1009 participants revealed that tibolone, a synthetic steroid 
with estrogenic, progestogenic, and weak androgenic actions, was found to be effective to 
decrease plasma Lp(a) concentrations by over 25% in postmenopausal women 68. A modest 
reduction of Lp(a) concentrations has been also observed with aspirin treatment 69. Cholesteryl 
ester transfer protein (CETP) inhibitors also decrease plasma LDL-cholesterol and Lp(a) 
concentrations, but the recent disappointment generated by evacetrapib (October 2015) raised 
significant doubts over the efficacy of  drugs in treating increased plasma Lp(a) concentrations 
70. However, the Defining the Safety of Anacetrapib in Patients at High Risk for Coronary Heart 
Disease (DEFINE) study showed an essential reduction of Lp(a) by 36.4% after 24-weeks of 
treatment on 2757 patients recruited from 20 countries using anacetrapib 71. 
 A dose-dependent reduction of Lp(a) up to 78% was also shown through therapy with a 
modified antisense oligonucleotide drug 72. The monoclonal antibodies targeting proprotein 
convertase subtilisin/kexin type 9 (PCSK9) can reduce Lp(a) 73-75. Indeed, various trials showed 
a median reduction of Lp(a) from baseline up to 35% 76. A pooled analysis of 150 mg every two 
weeks dosing from phase 2 trials showed the favorable impact of alirocumab on Lp(a) by over 
30% 77. The Program to Reduce LDL and CV Outcomes Following Inhibition of PCSK9 In 
Different Populations (PROFICIO) showed that evolocumab, another PCSK9 inhibitor (Amgen, 
12	
	
Thousand Oaks, CA), was effective to reduce Lp(a) by 29.5% (in a dose-dependent manner) in 
four randomized, double-blind phase 2 trials over a 12-week period 78. Two studies using meta-
analysis has shown  a 25% reduction of Lp(a)  79 and -0.94 (95%CI, -1.12 to -0.77) of the 
standard mean difference change in Lp(a) by treatment PCSK9 inhibitors 80. Furthermore, 
tocilizumab is a monoclonal antibody targeting the IL-6 receptor, which was found to be 
effective to decrease Lp(a) concentrations by 30% in rheumatoid arthritis individuals 81. Another 
important step in developing a drug which successfully target Lp(a) concentrations might be the 
inhibition of apo(a) synthesis by fibroblast growth factor 19 (FGF19) and farnesoid X receptor 82, 
83.  
 Some dietary supplements have been successfully evaluated for lowering plasma Lp(a) 
concentrations. A recent meta-analysis has demonstrated that oral L-carnitine significantly 
reduce Lp(a) concentrations (mean decrease, -8.82 mg/dL; p<0.001) 84. However, these results 
should be interpreted with caution since oral L-carnitine metabolization generates 
trimethylamine-N-oxide (TMAO), a product strongly involved in increasing CVD risk and 
accelerating atherosclerosis 85, 86. Adding dietary allicin from fresh garlic might be a solution to 
successfully inhibit the pathway of gut microbiota-dependent TMAO production 87. On the 
contrary, another meta-analysis on 6 randomized controlled trials and 151 participants did not 
show a significant effect of garlic on Lp(a) concentrations (mean reduction, 16.86%; p=0.12), 
despite the inverse association noticed between the changes in plasma concentrations of Lp(a) 
and duration of supplementation  - the significant effect was observed for the supplementation 
duration >12 weeks (-54.59%; p<0.001) 88. 
 
Current perspectives 
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 The role of Lp(a) as an independent risk factor of CVD events, irrespective of other coexisted 
risk factors, is critical. The knowledge of physicians, and consequently the frequency of 
measurements, is very limited (which is related to the lack of clear recommendations) 5. The 
measurement of Lp(a) also remains problematic 89-92, and its heterogeneity leads to difficulties 
when comparing the endpoints of the different studies 91. At present, immunoassays are generally 
available to measure Lp(a) levels, but when the antibodies for Lp(a) detection recognize the 
multiply repeated kringle IV-type 2 domain present in the apo(a) moiey, the apo(a) size can 
strongly impact assay results. Indeed, the composition of Lp(a), which contains apo(a), apoB100 
and various lipids, is probably the main source of inter-assay viability. Therefore, the levels of 
Lp(a)-cholesterol, although not commonly assessed in clinical trials, should be seen as a more 
suitable approach for standardizing (or harmonizing) Lp(a) measurement 89-92. One proposed 
solution was that Lp(a) should be expressed in nmol/L of protein, based on the relationship 
between the total number of Lp(a) particles and apoB 94. New methods for Lp(a) measurement 
are currently in development 91, 94. 
Consideration of the genetics of Lp(a) is important when using this measurement for CVD 
risk assessment. Recent studies have suggested that the common variants rs1045587 or 
rs3798220 at LPA locus are significantly associated with increased Lp(a) levels and increased 
CVD risk 20, 22. Both carriers of rs10455872 (OR, 1.70; 95% CI, 1.49 to 1.95) and rs3798220 
variants (OR, 1.92; 95% CI, 1.48 to 2.49) showed an increased risk of CHD 20. Similarly, the 
carriers of rs10455872 (OR, 1.32; 95% CI, 1.22 to 1.42) and rs3798220 variants (OR, 1.34; 95% 
CI, 1.18 to 1.54) showed an increased risk of coronary artery disease, and the carriers of the 
variants also showed an increased risk of ischemic stroke (OR, 1.10; 95% CI, 1.02 to 1.18) 22. On 
the other hand, rs10455872 variant is more common in Caucasians than in other populations 95. 
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No apparent relationship between rs3798220 variant and subsequent cardiovascular events was 
observed in Chinese Han patients with coronary artery disease 96. 
The genetic studies might provide further evidence of the role of Lp(a) in the development 
of cardio- and cerebro-vascular disease. Since genetic determinants are unaffected by 
environmental factors, the LPA genotype-scoring system might be useful to establish a 
personalized treatment 20, 22. Future studies should address these aspects in various ethnic and/or 
diseased populations. 
The oxidative modification of lipoproteins may be important in the pathophysiology of 
atherosclerosis 97, 98. Being a unique lipoprotrein subclass, Lp(a) is relatively easily oxidized. 
Various phenomena of Lp(a) oxidation and/or oxidative molecules capable of binding to Lp(a) 
have been observed in vessel walls 99, 100. Therefore, oxidized-Lp(a) levels might be more 
suitable markers for the development of cardio- and cerebro-vascular disease. An assay for 
oxidized-Lp(a) using the sandwich-ELISA method has been recently developed, thus generating 
an increased interest in oxidized-Lp(a) determination in CVD research 100-103. The monoclonal 
antibody obtained using oxidizing agents in this assay was shown to react only with oxidized 
Lp(a), but not with native Lp(a) and LDL 100. The antibody detected a specific epitope that 
appears when the Lp(a) particle has been exposed to oxidative stress 100. Although Lp(a) is easily 
oxidized, oxidized-Lp(a) is not well correlated to native Lp(a) level in our experience. Even in 
low oxidative Lp(a) environment, the mobility of oxidized-Lp(a) is changed, being different 
from that of native Lp(a) in agarose gel electrophoresis analysis 100. Additional assays for Lp(a) 
oxidation are needed 101, as are more studies to address the implication of Lp(a) in vascular 
pathologies. 
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 In addition to the role of high Lp(a) levels in various vascular diseases, other features of 
Lp(a) have received attention. In contrast to the pathogenic effects of high Lp(a) levels, low 
concentrations are also important in vascular medicine 104. A prospective study suggested a J-
curved phenomenon with a slight increase of cardio- and cerebro-vascular outcomes in the group 
of patients with very low Lp(a) levels and a larger increase in the group of patients with 
significantly increased Lp(a) levels 104, 105. The decreased values of Lp(a) have been associated 
with carotid atherosclerosis 105 and have been proposed as markers of cerebral hemorrhage risk 
based upon the results of a prospective population-based study 106. Although the mechanisms of 
these findings are not sufficiently understood, it is important to explain about the role of Lp(a) on 
vascular pathophysiology. Low blood lipids might induce angionecrosis and/or reflect impaired 
nutritional metabolism within the vessels 107, and Lp(a) particles might be involved in these 
mechanisms. Therefore, excessive lowering of Lp(a) may be seen as a double edged sword, thus 
reducing the potential beneficial effect of physiological concentrations of this lipoprotein and its 
metabolites against cancer 108. Lp(a) particles may also carry the molecules related to vascular 
dysfunction. Lp(a) can be a transporter through absorption of oxidized lipids in the circulation 
and vessel walls 109. An highly increased Lp(a) level induces atherogenic properties with 
oxidized lipids, while a very low Lp(a) level might show atherogenic properties and a 
detrimental metabolism of scavenging oxidized lipids. 
 Some questions remain in relation to the controversial anti-tumor function of Lp(a) 110. In 
experimental studies a reduction of tumor cells growth by apo(a) was demonstrated 111, 112. The 
degradation of apo(a) inside of Lp(a), produces various size of kringles and this process was 
associated with anti-angiogenesis and anti-tumor properties 110. In addition, although the 
biological mechanisms remain unclear, high Lp(a) levels were repeatedly detected in the very 
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elderly, suggesting that elevated Lp(a) might be linked with longevity 113. The putative anti-
cancer properties of Lp(a) and its metabolites may at least in part explain the association with 
longevity, but additional studies are warranted to define the potential beneficial effects exerted 
by Lp(a) at physiological concentrations. Some studies reported that high Lp(a) levels are 
predictive markers of CVD outcomes and including mortality, while others reported no apparent 
relationship between Lp(a) and nonvascular or all-cause mortality (Table 1) 28, 29. It is still 
unknown if these results are related to the influence of Lp(a) on cancer or longevity. A recent 
prospective study reported that high levels of Lp(a) are beneficial for cancer- and all-cause 
mortality 114. These findings may be increasingly important in the future when CVD events are 
more susceptible to treatment and the long life-expectancy results in an aging population. 
 
Conclusions 
The present paper outlines the current state of knowledge and evidence regarding the effects 
of Lp(a) on CVD risk by summarizing the results of the available data from meta-analyses and 
systematic reviews. The literature supports the predictive value of Lp(a) on CVD outcomes, 
although the effect size is modest. Lp(a) would also appear to have an effect on cerebrovascular 
(stroke) outcomes, although the effect appears to be smaller than that for CVD outcomes. 
Consideration of apo(a) isoforms and LPA genetics, in relation to circulating Lp(a) 
concentrations, may enhance improving the clinical practice in vascular medicine. We describe 
recent advances in Lp(a) research and highlight areas where further study is needed, including 
the measurement of Lp(a) and its involvement in additional pathophysiological processes. 
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Figure legend: 
Figure 1. Sketch of Lp(a)  
Lp(a): lipoprotein(a), apo(a): apolipoprotein(a), apoB: apolipoprotein B, LDL: low-density 
lipoprotein 
 
 
